# A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

> **NCT05197153** · PHASE2 · COMPLETED · sponsor: **Medigen Vaccine Biologics Corp.** · enrollment: 804 (actual)

## Conditions studied

- COVID-19 Vaccine

## Interventions

- **BIOLOGICAL:** Half dose of MVC-COV1901
- **BIOLOGICAL:** Full dose of MVC-COV1901
- **BIOLOGICAL:** AZD1222
- **BIOLOGICAL:** Half dose of mRNA-1273

## Key facts

- **NCT ID:** NCT05197153
- **Lead sponsor:** Medigen Vaccine Biologics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-22
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-10-28
- **Target enrollment:** 804 (ACTUAL)
- **Last updated:** 2023-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05197153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05197153, "A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05197153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*